Effect of Nifuroxazide on Proliferation, Migration, and Invasion of Thyroid Papillary Carcinoma Cells
Abstract
To explore the effect of nifuroxazide on proliferation, migration, and invasion of thyroid papillary carcinoma cells. Methods BCPAP and TPC-1 cell lines treated with different concentration (0, 1.25, 2.5, 5, 10, 20 μmol/L) of nifuroxazide, respectively. Cell viability and proliferation of BCPAP and TPC-1 was evaluated by MTT and colony formation assay. Apoptosis analysis and cell nuclear changes were determined by staining with Hoechst 33258 and visualized by a fluorescence microscope after treatment with nifuroxazide. Western blot analysis was used to evaluate protein expressions of apoptosis and invasion of BCPAP cells treated (48 h) with nifuroxazide. Transwell assay was conducted to evaluate ability of cell migration and invasion. Results After being treated with nifuroxazide (0, 1.25, 2.5 μmol/L and 0, 1.25 μmol/L) for 24, 48, 72 h respectively, decreased proliferations of BCPAP and TPC-1 cell lines were not obvious ( P>0.05). However, treated BCPAP and TPC-1 cells with higher concentration respectively (5, 10, 20 μmol/L and 5,10 μmol/L) of nifuroxazide for 24, 48, 72 h, the inhibitory effects were significantly obvious ( P<0.05), and the inhibitory effects were increased in a CM(155mm]concentration- and time-dependent manner. The inhibition in proliferation of TPC-1 cell with nifuroxazide (2.5, CM)]5 μmol/L) took effect from 72 h and 48 h ( P<0.05), respectively. Clone formations of BCPAP and TPC-1 cells were significantly inhibited after being exposed to nifuroxazide (2.5, 5 μmol/L) for 10 d ( P<0.05). Hoechst 33258 staining assay showed that nifuroxazide (10 μmol/L) treatment resulted in cell shrinking, nuclear fragmentation and formation of condensed nuclei with bright-blue fluorescence. After 48 h, the percentage of apoptotic cells of BCPAP and TPC-1 significantly increased respectively as the concentration of nifuroxazide with 10 μmol/L ( P<0.005). Pro-apoptotic protein CC-3 and Bax expression levels increased significantly ( P<0.05), and the expression of anti-apoptotic protein Bcl-2 decreased significantly （ P<0.05） in BCPAP cells after nifuroxazide-treatment (10 μmol/L) for 48 h. The percentage of migrations and invasions of BCPAP and TPC-1 significantly decreased ( P<0.05) in the presence of nifuroxazide (10 μmol/L, 48 h). Nifuroxazide (10 μmol/L) treatment significantly decreased the expressions of matrix metalloproteinase (MMP)-2 and MMP-9 in BCPAP cells（ P<0.05）. Expression of MMPs family inhibitor-tissue inhibitors of metalloproteinase (TIMP)-2 increased ( P<0.05). Conclusions Nifuroxazide inhibits the proliferation of thyroid cancer cells BCPAP and TPC-1, induceds the cell apoptosis by up-regulating the expressions of CC-3 and Bax proteins in vitro, and blocks migration and invasion of cells in vitro by reducing protein expressions of MMP-2 and MMP-9.
Keywords: Thyroid cancer, Nifuroxazide, Proliferation, Migration Invasion
Full Text:
PDFReferences
CHEN W, ZHENG R, BAADE PD. Et al. Cancer statistics in China. CA Cancer J Clin,2016,66(2): 115-132.
ZOU M, BAITEI EY, ALZAHRANI AS, et al. Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma. Thyroid,2014, 24(8);1256-1266.
PERROS P.BOELAERT K, COLLEY S, et al. Guidelines for the management of thyroid cancer. Clin Endocrinol (Oxf), 2014,81 Suppll: 1-122.
XING M, ALZAHRANI AS, CARSON KA, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA,2013,309( 14): 1493-1501.
MASUNARI A, TAVARES LC. A new class of nifuroxazide analogues; synthesis of 5-nitrothiophene derivatives with antimicrobial activity against multidrug-resistant Staphylococcus aureus. Bioorg Med Chem, 2007, 15 ( 12 ): 4229-4236.
NELSON EA, WALKER SR. KEPICH A, et al. Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3. Blood,2008,112( 13) :5095-5102.
ZHAO T, JIA H, CHENG Q, et al. Nifuroxazide prompts antitumor immune response of TCL-loaded ГХ' in mice with orthotopically-implanted hepatocarcinoma. Oncol Rep, 2017. 37(6);3405-3414.
YETH, YANG FF, ZHU YX, et al. Inhibition of Stat3 signaling pathway by nifuroxazide improves antitumor immunity and impairs colorectal carcinoma metastasis. Cell Death Dis, 2017, 8 (1): e2534[2018-07-15]. https://www. ncbi. nlm. nib. gov/pmc/articles/PMC5386364/. doi; 10. 1038/cddis. 2016.452.
ZHU Y, YE T, YU X, et al. Nifuroxazide exerts potent anti-tumor and anti-metastasis activity in melanoma. Sci Rep, 2016,6:20253.
YANG F. HU M, LEI Q, et al. Nifuroxazide induces apoptosis and impairs pulmonary metastasis in breast cancer model. Cell Death Dis,2015,6;el701[2018-07-15]. https:// www. ncbi. nlm. nib. gov/pmc/articles/PMC4385941/. doi: 10. 1038/cddis. 2015. 63.
NELSON EA, WALKER SR. KEPICH A, et al. Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3. Blood.2008,112(13) :5095-5102.
YANG FF, YU Y, LEI Q4etal. Lobaplatin arrests cell cycle progression, induces apoptosis and impairs migration and invasion in B16-F10 melanoma cell line in vitro. Biomed Pharmacother,2015, 69; 402-408[2018-07-15], https://doi. org/10. 1016/j. biopha. 2014. 12.011.
WANG F,SCOVILLE HD. HE XC, et al. Isolation and characterization of intestinal stem cells based on surface marker combinations and colony-formation assay. Gastroenterology. 2013. 145 (2): 383-395. el-e21 [2018-07- 15]. https;//doi. org/10. 1053/j. gastro. 2013. 04. 050.
ADAN A. ALIZADAG. KIRAZ Y. et al. Flow cytometry: basic principles and applications. Rev Biotechnol, 2017, 37 (2):163-176.
KRAMER N. WALZL A, UNGER C, et al. hi -vitro cell migration and invasion assays. Mutat Res,2013,752( 1): 10-24.
МАНМООD T, YANG PC. Western blot; technique, theory and trouble shooting. N Am J Med Sci,2012,4(9);429-434.
RICCI MS, ZONG WX. Chemotherapeutic approaches for targeting cell death pathways. Oncologist, 2006, 11 (4) ; 342- 357.
SUN LM, WANG XD. A new kind of cell suicide; mechanisms and functions of programmed necrosis. Trends Biochem Sci, 2014 ,39(12); 587-593.
QUAST SA, BERGER A, EBERLE J. ROS-dependent phosphorylation of Bax by wortmannin sensitizes melanoma cells for TRAIL-induced apoptosis. Cell Death Dis,2013,4: e839[2018-07-15]. https://www. ncbi. nlm. nih. gov/pmc/ articles/PMC3824654/. doi: 10. 1038/cddis. 2013. 344.
MORRISON JA.P1KE LA, LUND G,et al. Characterization of thyroid cancer cell lines in murine orthotopic and intracardiac metastasis models. Horm Cancer, 2015, 6( 2/3): 87-99.
LU P. ТАК AI K, WEAVER VM.etal. Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harb Perspect Biol.2011,3(12) ;pii;a005058.
LEE EJ, LEE SJ. KIM S, et al. Interleukin-5 enhances the migration and invasion of bladder cancer cells via ERK1/2- mediated MMP-9/NF-jcB/AP-l pathway: involvement of the p21 WAF1 expression. Cell Signal,2013,25( 10) :2025-2038.
OH SJ, JUNG SP, HAN J, et al. Silibinin inhibits TPA- induced cell migration and MMP-9 expression in thyroid and breast cancer cells. Oncol Rep,2013,29(4): 1343-1348.
BOURBOULIA D.JENSEN-TAUBMAN S.RITTLER MR, et al. Endogenous angiogenesis inhibitor blocks tumor growth via direct and indirect effects on tumor microenvironmen. Am J Pathol,2011,179(5);2589-2600.
WANG N. JIANG R, YANG JY, et al. Expression of TGF- |3l, SNAI1 and MMP-9 is associated with lymph node metastasis in papillary thyroid carcinoma. J Mol Histol, 2014,45(4):391-399.
RAJORIA S. SURIAND R, GEORGE A. et al. Estrogen induced metastatic modulators MMP-2 and MMP-9 are targets of 3. Sdiindolylmethane in thyroid cancer. PLoS One,2011, 6(1);el5879[2018-07-15]. https://doi.org/10. 1371/journal, pone. 0015879.
JIA W. GAO XJ, ZHANG ZD, et al. S100A4 silencing suppresses proliferation, angiogenesis and invasion of thyroid cancer cells through downregulation of MMP-9 and VEGF. Eur Rev Med Pharmacol Sci,2013,17(11): 1495-1508.
Refbacks
- There are currently no refbacks.
